What is Biometry?
Biometry operates as a specialized digital health platform dedicated to the remote monitoring and management of patients suffering from chronic conditions, with a primary focus on asthma. The company utilizes proprietary sensor technology to measure critical biomarkers, such as Fractional Exhaled Nitric Oxide (FeNO), which are essential for assessing medication adherence and treatment efficacy. By integrating these data points into a cohesive digital ecosystem, Biometry provides patients with personalized predictive risk models and actionable insights. Furthermore, the platform incorporates CDC-recognized, guideline-based self-management programs, which are designed to enhance patient education while simultaneously reducing the broader economic burden on healthcare systems. This dual approach of clinical precision and patient empowerment positions Biometry as a key player in the evolution of value-based care.
How much funding has Biometry raised?
Biometry has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2024): $5M with participation from Elevate Ventures, CareSource, and Dexcom
Key Investors in Biometry
Elevate Ventures
Elevate Ventures is an active participant in shaping the future of Indiana by investing in cross-sector innovation-driven companies at Pre-Seed, Seed, and Series A stages.
CareSource
CareSource is a nonprofit, multi-state health plan recognized as a national leader in managed care, serving millions of members across multiple states.
Dexcom
Dexcom, Inc. is a leading medical technology company that develops and manufactures continuous glucose monitoring systems for people with diabetes.
What's next for Biometry?
Looking ahead, the strategic deployment of this capital will likely focus on scaling the company's proprietary sensor infrastructure and deepening its integration with existing healthcare provider networks. As the industry shifts toward proactive, data-driven interventions, Biometry is poised to leverage its recent backing to refine its predictive risk algorithms and expand its reach into broader chronic respiratory markets. The involvement of strategic partners suggests a clear path toward commercial validation and potential integration into large-scale managed care programs. By prioritizing clinical outcomes and cost-efficiency, the company is set to navigate the complexities of the digital health landscape, aiming to transform standard asthma care into a more responsive, patient-centric model.
See full Biometry company page
